Abstract 162P
Background
Breast cancer (BC) is primarily a disease of older or post menopausal women. It has been suggested that BC arising in young women is a unique biological subset characterized by less hormone sensitivity and higher HER2 (epidermal growth factor receptor) expression. This study was performed to compare the tumour biology between pre menopausal (PrM) and post menopausal (PoM) women.
Methods
New diagnosis of early BC from 2011-2015 in the South East Cancer Centre were included. The patients were divided into PrM (
Results
Data from 497 patients were obtained. 235 (47.3%) were PrM and 262 (52.7%) were PoM. Age range PrM group vs PoM group (29-54 vs 55-91). The differences between the groups was statistically significant on pathology subtype (p = 0.003), T stage (p = 0.033), and N stage (p = 0.008). Ki67 and grade were not statistically significant. The mean ki67 across biology subtypes (ER/PR/HER2/Ki67) in the PrM group was higher. PrM group had more grade III disease (33.2% vs 30.9%). Table 1: Distribution of tumour biology according to menopausal status.
| Pre Menopausal n = 235 | Post Menopausal n = 262 | P value | |
|---|---|---|---|
| Age Range | 29-54 | 55-91 | ConclusionsPre menopausal women in this Irish population had poorer tumour biology compared to their Post menopausal counterpart. Aggressive measures should be taken in the treatment of these women to reduce the incidence of local recurrence and metastases. Clinical trial identificationNone Legal entity responsible for the studyUniversity Hospital Waterford FundingUniversity Hospital Waterford DisclosureAll authors have declared no conflicts of interest. Resources from the same sessionZUMA-3: A phase 1/2 multi-center study evaluation the safety and efficacy of KTE-C19 anti-CD19 CAR T cells in adult patients with relapsed/refractory B precursor acute lymphoblastic leukemia (R/R ALL)Presenter: Bijal Shah Session: Poster display Resources: Abstract ZUMA-2: A phase 2 multi-center study evaluating the efficacy of KTE-C19 (Anti-CD19 CAR T cells) in patients with relapsed/refractory Mantle cell lymphoma (R/R MCL)Presenter: Michael Wang Session: Poster Display Resources: Abstract ZUMA-1: A phase 2 multi-center study evaluating anti-CD19 chimeric antigen receptor (CAR) T cells in patients with refractory aggressive non-Hodgkin lymphoma (NHL)Presenter: Sattva Neelapu Session: Poster Display Resources: Abstract Younger age as a prognostic indicator in breast cancer: Correlation between clinical-pathologic factors and miRNAs and long-term follow-upPresenter: Maria Teresa Martinez Session: Poster display Resources: Abstract Window study of the PARP inhibitor rucaparib in patients with primary triple negative or BRCA1/2 related breast cancer (RIO)Presenter: Christy Toms Session: Poster display Resources: Abstract Whole exome sequencing (WES) and RNA sequencing (RNA-seq) in routine clinical practice for colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) patients (pts)Presenter: Géraldine Perkins Session: Poster display Resources: Abstract What is the optimal annual interpretive volume for a radiologist reading screening mammograms?Presenter: Asli Uluturk Session: Poster display Resources: Abstract What decides breast conservation versus mastectomy in the background of diverse sociocultural environment, an Indian studyPresenter: Poonamalle Padmanabhan Bapsy Session: Poster display Resources: Abstract Waiting time to diagnosis and treatment of the head and neck cancer in four institutions in PortugalPresenter: Ana Castro Session: Poster display Resources: Abstract Wait times for diagnosis and treatment of lung cancer: a single centre experiencePresenter: Catherine Labbe Session: Poster Display Resources: Abstract This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. For more detailed information on the cookies we use, please check our Privacy Policy.
|